Joining us at the midpoint of the week on the Daily Dive, is that of Dr Thomas Sawyer, COO of Cognetivity Neurosciences (CSE: CGN). Tom joins us on the show this afternoon to discuss the tech developed by Cognetivity that uses artificial intelligence and machine learning to detect the early onset of Alzeimer’s and dementia.
Cognetivity is a tech firm that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Through the use of AI and machine learning, the tech is able to detect the early onset of Alzheimer’s and dementia through testing the performance of large areas of the brain. The tech has acquired regulatory approval for use in both the UK and Europe, with further approvals in North America anticipated to occur.
Catch the full interview below.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
